Fierce Biotech Fundraising Tracker '25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M
Grin Therapeutics closed a $140 million Series D financing round, with $65 million invested by Angelini Pharma and $75 million from existing investor Blackstone Life Sciences23.
Simultaneously, Grin secured a licensing and collaboration deal with Angelini Pharma for the epilepsy disorder drug radiprodil, valued at up to $570 million, which includes a $50 million upfront payment and a $65 million equity investment from Angelini124.
The strategic partnership aims to develop and commercialize radiprodil outside North America, with plans to advance the drug into pivotal phase III trials for GRIN-related neurodevelopmental disorder (GRIN-NDD)25.
Angelini Pharma CEO Jacopo Andreose, PhD, will join the Grin Board of Directors as part of the collaboration2.
These combined transactions mark a significant validation and financial commitment to Grin's clinical development efforts in rare neurodevelopmental disorders25.
(Note:
While Syndeio's $90M fundraising is mentioned, no details appear in the provided results.)
Sources:
1. https://firstwordpharma.com/story/5966502
2. https://www.biospace.com/press-releases/grin-therapeutics-and-angelini-pharma-enter-into-exclusive-collaboration-to-develop-and-commercialize-radiprodil-outside-north-america
3. https://patrickwareing.com/news/grin-therapeutics-closes-140m-series-d-strikes-major-global-deal-with-angelini-pharma-for-radiprodil/
4. https://www.biospace.com/deals/epilepsy-biotech-nabs-up-to-570m-in-deal-with-italys-angelini-plus-140m-fundraising